Your browser doesn't support javascript.
loading
Feasibility of esophageal endoscopic submucosal dissection after radiofrequency ablation treatment in patients with Barrett's esophagus.
Koseki, Mako; Nishimura, Makoto; Nammour, Tarek; Nagao, Sayaka; Schattner, Mark A.
Afiliação
  • Koseki M; Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, New York, USA.
  • Nishimura M; Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Electronic address: nishimum@mskcc.org.
  • Nammour T; Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Nagao S; Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Schattner MA; Gastroenterology, Hepatology, and Nutrition Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Gastrointest Endosc ; 100(1): 128-131, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38340874
ABSTRACT
BACKGROUND AND

AIMS:

Radiofrequency ablation (RFA) is a well-established treatment for Barrett's esophagus (BE) in the United States. Similarly, endoscopic submucosal dissection (ESD) has been widely performed for early esophageal carcinoma. However, conducting ESD after RFA can be technically challenging. The aim of this study was to assess the feasibility and safety of ESD in patients with prior RFA.

METHODS:

This study was a single-center retrospective analysis of patients who underwent esophageal ESD after undergoing prior RFA treatment for BE.

RESULTS:

Of 44 esophageal ESD cases, 7 underwent prior RFA. In those 7 cases, the en bloc resection rate was 100%, and the R0 resection rate was 86%. No acute or delayed adverse events or rehospitalizations occurred in any patient.

CONCLUSIONS:

ESD may be a feasible and safe option for patients with a history of RFA. It could be considered for esophageal neoplasms in patients previously treated with RFA for BE.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esôfago de Barrett / Neoplasias Esofágicas / Estudos de Viabilidade / Ressecção Endoscópica de Mucosa / Ablação por Radiofrequência Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esôfago de Barrett / Neoplasias Esofágicas / Estudos de Viabilidade / Ressecção Endoscópica de Mucosa / Ablação por Radiofrequência Idioma: En Ano de publicação: 2024 Tipo de documento: Article